Anti-Hypertensive Drugs - Japan

Japan

Highlights

The Anti-Hypertensive Drugs market in Japan is expected to witness significant growth in the coming years.
According to projections, the revenue is estimated to reach ¥US$913.40m in 2024.
Furthermore, it is anticipated that the market will exhibit a steady annual growth rate of -0.13% (CAGR 2024-2029), leading to a market volume of ¥US$907.60m by 2029.
When compared globally, United States is expected to generate the highest revenue in the Anti-Hypertensive Drugs market, with an estimated value of US$12.29bn in 2024.
In Japan, the demand for anti-hypertensive drugs is on the rise due to the country's aging population and increasing prevalence of hypertension.

Key regions:

Market definitionIn-Scope/Out-of-scopeMarket structureReportsMethodology

The market for Anti-Hypertensive Drugs in Japan is experiencing significant growth in recent years.

Customer preferences: Japanese consumers are highly conscious of their health and prioritize preventative measures to avoid chronic diseases. This has led to a growing demand for anti-hypertensive drugs, especially among the aging population. Additionally, the Japanese government has been actively promoting the use of generic drugs, which has led to increased affordability and accessibility of these drugs for consumers.

Trends in the market: The Anti-Hypertensive Drugs market in Japan is witnessing a shift towards combination therapies, where two or more drugs are used in combination to achieve better blood pressure control. This trend is driven by the increasing prevalence of hypertension in Japan, which has resulted in a greater need for more effective treatments. Moreover, the market is also seeing a rise in the use of fixed-dose combinations, which simplifies dosing and improves patient adherence.

Local special circumstances: Japan has a rapidly aging population, with over a quarter of its population aged 65 or older. This demographic shift has led to an increase in the prevalence of hypertension, which is a major risk factor for cardiovascular diseases. Furthermore, the Japanese healthcare system is highly regulated, which has resulted in a slower adoption of new drugs compared to other developed countries.

Underlying macroeconomic factors: The Japanese economy has been experiencing a period of stagnation, with low economic growth and deflationary pressures. This has led to a greater focus on cost containment in the healthcare sector, which has resulted in greater scrutiny of drug prices. Additionally, the Japanese government has been promoting the use of generic drugs, which has led to increased competition and lower prices in the Anti-Hypertensive Drugs market.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.